Granisetron Hameln Pharma

Granisetron Hameln Pharma is an intravenous formulation of granisetron hydrochloride, a selective 5‑HT3 receptor antagonist used as an antiemetic. It is supplied as a prescription‑only product in the European market. The preparation is intended for administration by health‑care professionals to help prevent nausea and vomiting associated with chemotherapy or surgery. The medication is packaged in sterile vials and must be diluted according to the prescribing information before intravenous infusion.

Granisetron Hameln Pharma is indicated for the prevention of nausea and vomiting in specific clinical settings.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients receiving highly or moderately emetogenic regimens. - Prevention of postoperative nausea and vomiting (PONV) following general anesthesia. - Adjunct therapy for radiation‑induced nausea when combined with other antiemetics. - Use in patients who have not responded adequately to other 5‑HT3 antagonists.

The safety profile of Granisetron Hameln Pharma reflects the typical effects observed with 5‑HT3 receptor antagonists.

Common: - Headache - Constipation - Dizziness or light‑headedness - Fatigue or mild weakness - Injection‑site pain or erythema - Altered taste perception

Serious: - Severe allergic reactions (anaphylaxis, angioedema) - QT interval prolongation and associated arrhythmias - Cardiac arrhythmias such as torsades de pointes - Serotonin syndrome when combined with other serotonergic agents - Marked hypotension or cardiovascular collapse

When prescribing Granisetron Hameln Pharma, clinicians should consider several precautionary measures to ensure safe use.

- Assess cardiac history, especially prolonged QT interval; a baseline ECG may be recommended. - Use cautiously in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia. - Evaluate for known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Adjust therapy in patients with hepatic impairment; monitor for increased exposure. - Consider potential effects on fetal development; use only if benefits outweigh risks during pregnancy. - Monitor for signs of constipation or bowel obstruction in at‑risk patients.

Granisetron Hameln Pharma may interact with other medications that affect cardiac conduction or serotonin pathways.

Avoid: - Concurrent use with other QT‑prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics). - Co‑administration with other 5‑HT3 antagonists or serotonergic drugs (e.g., ondansetron, tramadol) may increase risk of serotonin syndrome.

Use with caution: - Combination with CYP3A4 inhibitors or inducers may alter granisetron plasma levels. - Use alongside drugs that cause electrolyte shifts (diuretics) may exacerbate QT risk. - Concomitant use with anesthetic agents that depress respiration should be monitored.